Home › Funds › Yiheng Capital Management, L.P. › VRDN

Yiheng Capital Management, L.P. position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Yiheng Capital Management, L.P. reported holding 400,464 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$8.2M, representing 3.20% of its reported portfolio and ranking #11 among its reported holdings. Yiheng Capital Management, L.P. has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)400.46K sh
Reported value held$8.25M
Portfolio Weight3.20%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Yiheng Capital Management, L.P.'s VRDN position evolved

Yiheng Capital Management, L.P. first disclosed a stake in VRDN in Q3 2023 at 1,228,534 shares (US$18.8M). The position peaked in Q4 2023 at 1,228,534 shares, worth US$26.8M. Across 13 filings, Yiheng Capital Management, L.P. increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 400,464 shares valued at US$8.2M. Notable position changes include a 33% trim in Q1 2025 (shares rose 4% over the following quarter), a 58% trim in Q4 2025 (shares fell 37% over the following quarter), a 92% increase in Q2 2026 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.23M $18.85M New
Q4 2023 1.23M $26.76M Hold
Q1 2024 948.13K $16.60M Reduce
Q2 2024 948.13K $12.34M Hold
Q3 2024 847.89K $19.29M Reduce
Q4 2024 750.26K $14.38M Reduce
Q1 2025 500.26K $6.74M Reduce
Q2 2025 500.26K $6.99M Hold
Q3 2025 500.26K $10.80M Hold
Q4 2025 208.74K $6.50M Reduce
Q1 2026 208.74K $4.08M Hold
Q2 2026 400.46K $7.36M Add
Q3 2026 400.46K $8.25M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Yiheng Capital Management, L.P. held VRDN?

Yiheng Capital Management, L.P. has disclosed VRDN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Yiheng Capital Management, L.P.'s current position in VRDN?

As of Q3 2026, Yiheng Capital Management, L.P. holds 400.46K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $8.25M, representing 3.20% of its reported portfolio and ranking #11.

Has Yiheng Capital Management, L.P. been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Yiheng Capital Management, L.P. held unchanged its position in VRDN. The position peaked in Q4 2023 at 1.23M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.